Simplification to Efavirenz-TDF-FTC

STUDY 073
Study Design: Study 073

- **Background**: Randomized, controlled, open label phase 3 trial evaluating a simplification strategy for patients suppressed on baseline ART by switching to a single-tablet regimen of efavirenz-tenofovir DF-emtricitabine once daily.

- **Inclusion Criteria** (n = 300)
  - Age ≥18 years
  - HIV RNA ≤200 copies/mL for ≥3 months
  - No new AIDS-defining conditions in past 30 days
  - On 1st ART regimen or viral suppression on previous protease inhibitor-based therapy at time of prior therapy switch

- **Treatment Arms**
  - Switch arm: Efavirenz-tenofovir DF-emtricitabine
  - Stay arm: Maintain baseline ART

Simplification to Efavirenz-TDF-FTC
Study 073: Result

Week 48 Virologic Response by RNA Threshold

Study 073: Subgroup Analysis Result

Week 48 Virologic Response, by Baseline Regimen (ITT Analysis, NC=F)

**Interpretation**: “Simplification to EFV/FTC/TDF maintained high and comparable rates of virologic suppression versus stay on baseline regimen (SBR) through 48 weeks.”
The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.